Почки и вегетативная дисфункция у детей и подростков  (часть I)

L.I. Vakulenko

doi:10.22141/2307-1257.9.2.2020.203408

Authors

L.I. Vakulenko State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine http://orcid.org/0000-0003-3823-6134

DOI:

https://doi.org/10.22141/2307-1257.9.2.2020.203408

Keywords:

children, chronic kidney disease, autonomic dysfunction, arterial hypertension

Abstract

The article discusses the mechanisms of interaction, development and progress of cardiovascular complications in children and adolescents with chronic kidney disease. The dominant role of autonomic dysfunction in the development of cardiovascular disorders is emphasized. The mechanisms are described by which an increase in the activity of sympathetic part of autonomic nervous system leads to kidney damage. Interaction of sympathetic nervous system and renin-angiotensin system during the formation of cardiovascular and kidney diseases is considered as a component of adaptive process of the body. The universal pathogenetic factor that accompanies the development of autonomic dysfunction and chronic kidney disease in children and adolescents is activation of renin-angiotensin system. The general mechanisms for the development of cardiorenal disorders determine further unidirectional approaches to the diagnosis and treatment.

Downloads

Download data is not yet available.

References

Raina R, Nair N, Chakraborty R, Nemer L, Dasgupta R, Varian K. An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome. Cardiol Res. 2020;11(2):76–88. doi:10.14740/cr955.

Ivanov DD, Kuryata OV, Garmysh IP. Renin angiotensin-aldosterone system blockers: chronic kidney disease and cardiovascular risk. Počki. 2018;7(2):81–90. doi:10.22141/2307-1257.7.2.2018.127393. (in Russian).

Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019;139(16):e840–e878. doi:10.1161/CIR.0000000000000664.

Ronco C, Bellasi A, Di Lullo L. Cardiorenal Syndrome: An Overview. Adv Chronic Kidney Dis. 2018;25(5):382–390. doi:10.1053/j.ackd.2018.08.004.

Olowu WA. Epidemiology, pathophysiology, clinical characteristics and management of childhood cardiorenal syndrome. World J Nephrol. 2012;1(1):16–24. doi:10.5527/wjn.v1.i1.16.

Tian J, Niu L, An X. Cardiovascular risks in chronic kidney disease pediatric patients. Exp Ther Med. 2017;14(5):4615–4619. doi:10.3892/etm.2017.5117.

Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol. 2012;23(4):578–585. doi:10.1681/ASN.2011111115.

Hsu CN, Lu PC, Lo MH, Lin IC, Tain YL. The Association between Nitric Oxide Pathway, Blood Pressure Abnormalities, and Cardiovascular Risk Profile in Pediatric Chronic Kidney Disease. Int J Mol Sci. 2019;20(21):5301. doi:10.3390/ijms20215301.

Skrzypczyk P, Okarska-Napierała M, Stelmaszczyk-Emmel A, Górska E, Pańczyk-Tomaszewska M. Renalase in children with chronic kidney disease. Biomarkers. 2019;24(7):638–644. doi:10.1080/1354750X.2019.1642957.

Wilson AC, Schneider MF, Cox C, et al. Prevalence and correlates of multiple cardiovascular risk factors in children with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(12):2759–2765. doi:10.2215/CJN.03010311.

Vidi SR. Role of hypertension in progression of chronic kidney disease in children. Curr Opin Pediatr. 2018;30(2):247–251. doi:10.1097/MOP.0000000000000595.

Barletta GM, Flynn J, Mitsnefes M, et al. Heart rate and blood pressure variability in children with chronic kidney disease: a report from the CKiD study. Pediatr Nephrol. 2014;29(6):1059–1065. doi:10.1007/s00467-013-2737-8.

Suessenbach FK, Burckhardt BB. Levels of angiotensin peptides in healthy and cardiovascular/renal-diseased paediatric population-an investigative review. Heart Fail Rev. 2019;24(5):709–723. doi:10.1007/s10741-019-09797-y.

Ivanov DD. Nephrology under the microscope: interdisciplinary aspects. Kidneys and arterial hypertension. UMJ. 2019;(132):32–33. (in Ukrainian).

Vakulenko LI. 24-hour blood pressure profile in children with chronic pyelonephritis and chronic kidney disease stages I-III. Počki. 2019;8(3):139–145. doi:10.22141/2307-1257.8.3.2019.176451.

Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017;140(3):e20171904. doi:10.1542/peds.2017-1904.

Wühl E, Schaefer F. Treatment of Hypertension in Chronic Kidney Disease. In: Lurbe E, Wühl E, editors. Hypertension in Children and Adolescents: New Perspectives. Geneva, Switzerland: Springer International Publishing; 2019. 239-255 pp. doi:10.1007/978-3-030-18167-3.

Halbach S, Flynn J. Treatment of hypertension in children with chronic kidney disease. Curr Hypertens Rep. 2015;17(1):503. doi:10.1007/s11906-014-0503-3.

Kamath N, Iyengar A, George N, Luyckx VA. Risk Factors and Rate of Progression of CKD in Children. Kidney Int Rep. 2019;4(10):1472–1477. doi:10.1016/j.ekir.2019.06.004.

Becker BK, Zhang D, Soliman R, Pollock DM. Autonomic nerves and circadian control of renal function. Auton Neurosci. 2019;217:58–65. doi:10.1016/j.autneu.2019.01.003.

Vein AM, Voznesenskaia TG, Vorob'eva OV, et al., authors; Vein AM, editor. Vegetativnye rasstroistva: klinika, diagnostika, lechenie [Vegetative disorders: clinic, diagnosis, treatment]. Moscow: MIA; 2010. 637 р. (in Russian).

Neudakhin EV. Substantiation of energotropic therapy of vegetative disorders in children. RMJ. 2018;26(2-2):107–112. (in Russian).

Chutko LS, Surushkina SIu, Iakovenko EA, Kornishina TL. Vegetative-vascular dystonia in children and adolescents. Clinical and psychophysiological manifestations and therapy (review). Praktika pediatra. 2019;(3):17–21. (in Russian).

Majdannyk VG, Mitjurjajeva-Kornijko IO, Kuhta NM, Gnyloskurenko GV. Vegetatyvni dysfunkcii' u ditej. Paroksyzmal'na vegetatyvna nedostatnist': monografija [Vegetative dysfunctions in children. Paroxysmal autonomic failure: monograph]. Kyiv: Logos; 2017. 300 p. (in Ukrainian).

Borysova TP, Abaturov AE. Clinical manifestations and correction of autonomic dysfunction in children and adolescents. Zdorov’e rebenka. 2018;13(6):588–594. doi:10.22141/2224-0551.13.5.2018.143165. (in Russian).

Mikhieieva TM, Nechytailo DYu, Poniuk VV, Fomina TP. Features of the vegetative state and arterial pressure level in children with chronic gastroduodenal pathology. Zaporozhye Medical Journal. 2018;20(5):651–654. doi: 10.14739/2310-1210.2018.5.141662. (in Ukrainian).

Belyaeva LM, Kolupaeva EA, Korol SM, Mikulchyk NV. Syndrome of vegetative dysfunction in children: myths and reality. Meditsinskie novosti. 2013;(5):5–15. (in Russian).

Zakharova IN, Tvorogova TM, Pshenichnikova II. Current guidelines for diagnosis and treatment of vegetative dystonia in children and adolescents. Meditsinskiy sovet. 2016;(16):116–123. doi:10.21518/2079-701X-2016-16-116-123. (in Russian).

Ostroumova OD, Kochetkov AI, Guseva TF, Zykova AA. Sympathtic nervous system activation in pathogenesis of development of essential hypertension and its role in target-organs damage in young and middle aged adults: the cardioprotective capabilities of Bisoprolol. Kardiologiia. 2018;58(3):63–72. doi:18087/cardio.2018.3.10100. (in Russian).

Agapitov LI, Cherepnina IV. Diagnostics and treatment of arterial hypertension in children and adolescents overview of new clinical guidelines of the American Academy of Pediatrics. Rossijskij vestnik perinatologii i pediatrii. 2019;64:(4):114–127. doi:10.21508/1027-4065-2019-64-4-114-127. (in Russian).

Writing Group Members, Mozaffarian D, Benjamin EJ, et al. Executive Summary: Heart Disease and Stroke Statistics –2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):447–454. doi:10.1161/CIR.0000000000000366.

Parati G, Esler M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33(9):1058–1066. doi:10.1093/eurheartj/ehs041.

Kaur J, Young BE, Fadel PJ. Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms. Int J Mol Sci. 2017;18(8):1682. doi:10.3390/ijms18081682.